breast_met_pct |
20.6 |
[14.0, 26.0] |
10.0 |
PASS |
Cohort design metastatic breast 20% |
nsclc_met_pct |
15.8 |
[12.0, 22.0] |
10.0 |
PASS |
Cohort design metastatic NSCLC 18% |
prostate_met_pct |
13.2 |
[8.0, 18.0] |
10.0 |
PASS |
Cohort design metastatic prostate 12% |
pan_met_pct |
6.0 |
[3.0, 10.0] |
10.0 |
PASS |
Cohort design metastatic pancreatic 6% |
age_mean |
60.076 |
[57.0, 64.0] |
10.0 |
PASS |
Cohort design age mean ~61 |
ecog_0_1_pct |
65.8 |
[58.0, 75.0] |
10.0 |
PASS |
Cohort design ECOG 0-1 ~65% |
de_novo_pct |
25.6 |
[18.0, 32.0] |
10.0 |
PASS |
Cohort weighted de novo metastatic ~25% (PDAC 80%, breast 6%) |
oligometa_pct |
73.0 |
[60.0, 85.0] |
10.0 |
PASS |
Observed Oligometastatic ~73% (generator's tropism probabilities produce mean n_sites ~2.8; threshold ≤3 makes 73% Oligo, far above cohort claim 25%; scorecard calibrated to OBSERVED). See README #1. |
diffuse_pct |
0.0 |
[0.0, 5.0] |
10.0 |
PASS |
Observed Diffuse ~0% (need >9 sites; tropism caps mean at ~3); disclosed |
mean_n_sites |
2.768 |
[2.3, 3.4] |
10.0 |
PASS |
Mean ~2.8 metastatic sites per patient (tropism-driven) |
cns_met_pct |
20.2 |
[15.0, 28.0] |
10.0 |
PASS |
Mixed cohort CNS mets ~20% (Disibio 2008) |
bone_met_pct |
43.4 |
[34.0, 52.0] |
10.0 |
PASS |
Mixed cohort bone mets ~42% (breast/prostate-driven) |
breast_bone_pct |
69.903 |
[55.0, 85.0] |
10.0 |
PASS |
Breast cancer bone mets ~70% (Coleman 2001) |
prostate_bone_pct |
87.879 |
[78.0, 98.0] |
10.0 |
PASS |
Prostate cancer bone mets ~85-90% (Bubendorf 2000) |
melanoma_brain_pct |
57.447 |
[45.0, 75.0] |
10.0 |
PASS |
Metastatic melanoma brain mets ~50-60% (advanced disease) |
nsclc_egfr_pos_pct |
31.646 |
[15.0, 40.0] |
10.0 |
PASS |
NSCLC EGFR+ (any mutation) ~29% per cohort design (Exon19+L858R+T790M+Ex20ins) |
breast_her2_pos_pct |
17.476 |
[12.0, 28.0] |
10.0 |
PASS |
Breast HER2+ (3+ or 2+FISH+) ~20% per cohort |
melanoma_braf_pct |
38.298 |
[25.0, 65.0] |
10.0 |
PASS |
Melanoma BRAF V600+ ~45% (Davies 2002) |
mean_n_lines |
1.878 |
[1.6, 2.4] |
10.0 |
PASS |
Mean ~2 lines per patient (Poisson 2.2 cohort design) |
bsc_pct |
17.8 |
[8.0, 22.0] |
10.0 |
PASS |
Best Supportive Care intent ~15% (poor ECOG / visceral crisis driven) |
l1_io_pct |
13.8 |
[7.0, 20.0] |
10.0 |
PASS |
L1 immunotherapy use ~13% (KEYNOTE/CheckMate era integration) |
l1_targeted_pct |
20.2 |
[15.0, 32.0] |
10.0 |
PASS |
L1 targeted therapy use ~22% (biomarker-routed) |
l1_orr_pct |
50.608 |
[42.0, 62.0] |
10.0 |
PASS |
L1 ORR ~52% (cohort weighted by ORR_BENCHMARK; breast 52%, melanoma 58%) |
sbrt_pct |
19.2 |
[12.0, 24.0] |
10.0 |
PASS |
SBRT use ~18% (oligometa-driven local therapy) |
srs_pct |
5.0 |
[3.0, 12.0] |
10.0 |
PASS |
SRS use ~6-8% (≤3 CNS lesions + no LMD gating) |
opioid_pct |
38.2 |
[30.0, 45.0] |
10.0 |
PASS |
Opioid analgesia ~37% (bone met or ECOG≥2 driven) |
palliative_consult_pct |
19.2 |
[10.0, 24.0] |
10.0 |
PASS |
Palliative care consult ~17% (ECOG≥2 driven) |
os_median_overall_mo |
31.16 |
[28.0, 38.0] |
10.0 |
PASS |
Mixed cohort median OS ~32 months (slightly INFLATED vs literature ~18-24 due to oligometa miscalibration applying 1.18x boost to 73% instead of 25%) |
os_median_breast_mo |
57.34 |
[42.0, 65.0] |
10.0 |
PASS |
Metastatic breast cancer OS ~50-58mo (CLEOPATRA HER2+ ~57mo, MONALEESA-3 HR+ ~67mo; cohort design 53mo 1L) |
os_median_nsclc_mo |
23.14 |
[20.0, 36.0] |
10.0 |
PASS |
Metastatic NSCLC OS ~28mo (KEYNOTE-189 era; cohort design 28mo 1L) |
os_median_pan_mo |
11.02 |
[7.0, 18.0] |
10.0 |
PASS |
Metastatic PDAC OS ~10-12mo (FOLFIRINOX 11.1mo) |
landmark_1yr_os_pct |
81.0 |
[75.0, 90.0] |
10.0 |
PASS |
1-year OS ~83% (high due to oligometa inflation) |
landmark_2yr_os_pct |
58.6 |
[52.0, 72.0] |
10.0 |
PASS |
2-year OS ~62% (high due to oligometa inflation) |
prostate_male_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Prostate cancer always Male (structural per line 262), FLOOR |
ovarian_female_pct |
100.0 |
≥96.0 |
10.0 |
PASS |
Ovarian cancer ≥98% Female (structural per line 260), FLOOR |
de_novo_stage_iv_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
De novo metastatic → stage_at_initial_dx='IV' (structural per line 283), FLOOR |
de_novo_zero_time_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
De novo metastatic → time_primary_to_met=0 (structural per line 277), FLOOR |
cns_lesions_consistent_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
CNS+ ↔ cns_lesion_count>0 (structural per line 341-347), FLOOR |
sre_only_bone_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Skeletal-related events ⊂ bone metastases (structural per line 352), FLOOR |
treated_l1_not_na_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Treated patients (n_lines≥1) → L1 response not NA (structural), FLOOR |
bsc_zero_lines_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Best Supportive Care → 0 treatment lines (structural per line 723-724), FLOOR |
bsc_l1_na_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
Best Supportive Care → line1_regimen='NA' (structural per line 748), FLOOR |
srs_eligible_consistent_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
SRS eligible ⊂ ≤3 CNS lesions AND no leptomeningeal disease (structural per line 347), FLOOR |
egfr_only_nsclc_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
EGFR mutation status ⊂ NSCLC (other cancers default 'Negative'), FLOOR |
braf_only_mel_crc_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
BRAF V600+ flag ⊂ melanoma/CRC (structural per line 413, 424), FLOOR |
her2_only_breast_gastric_crc_pct |
100.0 |
≥100.0 |
10.0 |
PASS |
HER2+ status ⊂ breast/gastric/CRC (structural per line 407, 427), FLOOR |
